You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
科興製藥(688136.SH):公司產品EPO在巴西、菲律賓等國家已成為當地EPO領先品牌產品
格隆匯 01-26 16:00

格隆匯1月26日丨科興製藥(688136.SH)披露投資者關係活動記錄表顯示,公司產品在海外銷售已近20年,建立了相對完整的海外商業體系,在海外產品註冊、海外開拓和營銷、海外GMP合規審計等方面積累了豐富資源與商業化能力,在新興市場國傢俱有較為豐富的商業化經驗,已通過巴西、菲律賓、印度尼西亞等約40個國家和地區的市場準入並實現銷售,銷售網絡已100%覆蓋人口過億的新興國家市場,已建立穩固且長期合作的客户超過100個。公司產品EPO在巴西、菲律賓等國家已成為當地EPO領先品牌產品。

公司擁有從產品規劃與諮詢、海外臨牀方案制訂、海外上市註冊、協助GMP核查認證、商業化等全流程服務能力。2021年以來,公司先後與國內多家藥企簽署協議,截至目前,公司已獲得10款生物類似藥、化學藥在歐盟及海外新興市場國家的銷售權益,在自免領域、抗腫瘤領域、代謝病領域形成豐富的產品組合,如在乳腺癌治療領域,公司已引進白蛋白紫杉醇、曲妥珠單抗、貝伐珠單抗和奈拉替尼、艾立布林等5款產品,形成了在重點腫瘤領域的產品矩陣。

公司將持續貫徹“海外商業化”戰略,致力於成為國內領先的生物類似藥/創新藥出海的商業化平台。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account